Whitehawk Therapeutics, Inc. (NASDAQ: WHWK)

Whitehawk Therapeutics Inc is a clinical stage oncology therapeutics company that applies advanced technologies to established tumor biology with the goal of delivering improved cancer treatments. The company focuses on developing antibody drug conjugates that use a novel linker payload platform called CPT113 to target validated tumor antigens. Its lead product candidates are HWK007 directed at PTK7, HWK016 directed at membrane bound MUC16 and HWK206 a biparatopic ADC targeting SEZ6. Whitehawk Therapeutics Inc operates with a virtual model that relies on outsourced research development and manufacturing through partners such as WuXi Biologics and Hangzhou DAC. The company was originally incorporated as Zeta Acquisition Corp II and underwent several name changes before adopting the Whitehawk Therapeutics Inc name in March 2025 following the divestiture of its FYARRO business.

We currently do not have any commercial product sales following the divestiture of the FYARRO business in March 2025. Historically the company generated net product sales of $7.1 million for the year ended December 31 2025 and $26.0 million for the year ended December 31 2024 from the FYARRO product. The divestiture transaction yielded a cash payment of $102.4 million which strengthens the company’s financial position. Future revenue will depend on the successful development regulatory approval and commercialization of our ADC pipeline. We may receive milestone payments royalties or other consideration under our licensing agreement with WuXi Biologics and Hangzhou DAC for the ADC Therapies.

Whitehawk Therapeutics Inc occupies a niche in the fast growing antibody drug conjugate market where it differentiates itself through its CPT113 linker payload technology that offers increased stability in blood circulation reduced free payload release and enhanced tumor potency compared with first generation ADCs. The company faces competition from large pharmaceutical and biotechnology firms such as AbbVie Daiichi Sankyo Eli Lilly Genmab GlaxoSmithKline Gilead Kelun Mersana Sanofi Roche Pfizer Zymeworks Ideaya Biocytogen and others that are also developing next generation ADCs with alternative payloads and linker systems. Its competitive advantages include a proprietary carbon bridge cysteine re pairing bioconjugation method a triple peptide intracellular cleavage site and PEG based masking that together aim to improve safety margins and therapeutic index. The company also benefits from a management team with extensive experience in oncology drug development and commercialization at major pharma companies. The antibody drug conjugate market was estimated at nearly $11 billion in sales at the end of 2024 and is projected to exceed $23 billion by 2030 with some forecasts reaching $50 billion providing a sizable opportunity for differentiated players.

The company intends to serve hospitals oncology clinics and other healthcare providers that treat patients with solid tumors such as non small cell lung cancer ovarian cancer endometrial cancer and neuroendocrine tumors. Specific customer names are not disclosed in the filing but the target market includes medical institutions and physicians involved in cancer care. Whitehawk Therapeutics Inc also anticipates engagement with payors and reimbursement agencies to secure coverage for its future products should they obtain regulatory approval. The overall customer base comprises entities involved in the diagnosis treatment and management of cancer patients across various care settings.